5[1]Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988, 37:1595-1599.
6[2]Marchesini G, Brizi M, Bianchi G,et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabe tes, 2001, 50: 1844-1850.
7[3]Norman RJ, Kidson WJ, Cuneo RC, et al. Metformin and intervention in polycystic ovary syndrome. Endocrine Soci ety of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. Med J Aust, 2001,174: 580-583.
8[4]Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular mor bidity and mortality associated with the metabolic syn drome. Diabetes Care, 2001, 24: 683-689.
9[8]Groop L, Orho-Melander M. The dysmetabolic syndrome, J Intem Med, 2001, 250: 105-120.
10[9]Wilson SH, Kennedy FP, Garratt KN. Optimisation of themanagement of patients with coronary heart disease and type 2 diabetes mellitus. Drugs Aging, 2001, 18: 325-333.
2Kelly AS,Steinberger J,Jacobs DR,et al.Predicting cardiovascular risk in young adulthood from the metabolic syndrome,its component risk factors,and a cluster score in childhood[J].Int J Pediatr Obes,2010,11(12):218-222.
3Kim YI,Kim CH,Choi CS.et al.Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population[J].Diabetes Research and Clinical Practice,2001,52:145-152.
4Mitsnefes MM.Cardiovascular complications of pediatric chronic kidney disease[J].Pediatr Nephrol,2008,23(1):27-39.
5Lambers Heerspink HJ,Fowler MJ,Volgi J,et al.Rationale for and study design of the sulodexide trials in Type 2 diabetic,hypertensive patients with urinary albumin excretion rate or overt nephropathy[J].Diabet Med,2007,11(24):1290-1295.
6Strecker T,Dieterle A,Reeh PW,et al.Stimulated release of calcitonin gane-related peptide from the human right atrium in patients with and without diabetes mellitus[J].Peptides,2006,27(12):3255-3260.
